Atrial fibrillation (AF) is the most common sustained arrhythmia associated with significant morbidity and mortality. The mechanisms underlying the pathogenesis of AF are poorly understood, although electrophysiological remodeling has been described as an important initiating step. There is growing evidence that oxidative stress is involved in the pathogenesis of AF. Many known triggers of oxidative stress, such as age, diabetes, smoking, and inflammation, are linked with an increased risk of arrhythmia. Numerous preclinical studies and clinical trials reported the importance of antioxidant therapy in the prevention of AF, using vitamins C and E, polyunsaturated fatty acids, statins, or nitric oxide donors. The aim of our work is to give a current overview and analysis of opportunities, challenges, and benefits of antioxidant therapy in AF.

• Klíčová slova
• Antioxidants, Atrial fibrillation, Atrial remodeling, Gene therapy, Oxidative stress, Prevention,
• MeSH
• akční potenciály MeSH
• antiarytmika farmakologie   MeSH
• antioxidancia terapeutické užití   MeSH
• fibrilace síní farmakoterapie   genetika   metabolismus   patofyziologie   MeSH
• genetická terapie metody   MeSH
• lidé MeSH
• oxidační stres účinky léků   genetika   MeSH
• remodelace síní účinky léků   MeSH
• rizikové faktory MeSH
• srdeční frekvence účinky léků   MeSH
• srdeční síně účinky léků   metabolismus   patofyziologie   MeSH
• zvířata MeSH
• Check Tag
• lidé MeSH
• zvířata MeSH
• Publikační typ
• časopisecké články MeSH
• přehledy MeSH
• Názvy látek
• antiarytmika MeSH
• antioxidancia MeSH